US/UK/Canada

Share

Contacts

  • Ann Charlotte Svensson

    Investor Relations


    +46 70 285 72 62

    • Links

    Pick a time period -
    Tags ( Active)

    Gradientech strengthens its commercial management team

    The diagnostics company Gradientech today announces that AnnaLotta Schiller Vestergren has been appointed as the company’s Chief Commercial Officer and part of the management team. AnnaLotta has extensive experience with international commercial organisations, with nearly 30 years of leading positions in life science and diagnostics.“I´m very pleased to welcome AnnaLotta to join the Gradientech team. With a background in molecular biology and bacteriology and extensive experience in international sales and business development from major life science companies as well as smaller emerging

    Gradientech unveals European clinical study data

    The diagnostics company Gradientech today announces the publication of data from the large multicenter clinical study of the QuickMIC® system in collaboration with leading European hospitals. QuickMIC is the today fastest diagnostic system on the market for antibiotic susceptibility testing (AST) of sepsis samples.Clinical study data from the multicenter performance evaluation of the QuickMIC system shows that QuickMIC is highly accurate compared to the reference testing method for AST, broth microdilution. QuickMIC provides 95.6% agreement with the reference MIC values (Minimum Inhibitory

    Gradientech´s distributor Triolab starts its first commercial evaluation with QuickMIC[®] in Sweden

    The diagnostics company Gradientech today announces that its assigned distributor for Sweden, Triolab AB, will start its first commercial evaluation of the QuickMIC® system at the Kalmar County Hospital.The Kalmar County Hospital provides diagnostic services for microorganisms such as bacteria, fungi, and viruses across its entire region in southern Sweden. The clinical microbiology department at Kalmar County Hospital will evaluate the performance of the QuickMIC system in comparison to their current routine antibiotic susceptibility testing (AST) method. The study will include samples

    New clinical study to evaluate QuickMIC® in the diagnostic workflow of urosepsis

    Uppsala, Sweden, March 5, 2024. The diagnostics company Gradientech today announces the start of a new prospective and observational QuickMIC® study in collaboration with Assoc. Prof. Martin Sundqvist at Örebro University Hospital.The study, initiated by Dr Sundqvist, will investigate the clinical utility of a new rapid workflow for prediction of optimal antibiotic treatment for patients with urosepsis. Urosepsis is caused by infections of the urinary tract where the sepsis causing bacteria are hence present in the urine and often, but not always, also in the patient’s blood. Results

    Gradientech: Year-end report 2023

    Gradientech AB (publ) year-end report for 2023 is now available on the company's website www.gradientech.se.Fourth quarter 2023 · Net sales amounted to SEK 376 thousand (831). · Net profit/loss amounted to SEK -17,810 thousand (-16,409). · Earnings per share before and after dilution were SEK -1.00 (-1.03). · Cash flow from operating activities amounted to SEK -14,637 thousand (-19,550). · Cash and cash equivalents amounted to SEK 10,811 thousand (21,177) as of December 31, 2023. · Equity amounted to SEK 48,451 thousand (46,578) as of December 31, 2023. · In October,

    All-time high in QuickMIC® abstracts at ECCMID 2024

    The diagnostics company Gradientech today announces that six QuickMIC® abstracts will be presented at the 34th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Barcelona, Spain 27-30 April 2024.ECCMID is the world’s premier meeting place for clinical microbiologists and infectious disease specialists, gathering over 14,000 delegates yearly. This year, a record 7,000+ abstracts have been submitted, setting the stage for an exceptional event in April. At ECCMID 2024, six different abstracts with data from independent European studies will demonstrate that

    Gradientech completes successful pre-clinical testing in the US

    The diagnostics company Gradientech today announces the successful completion of its pre-clinical testing of the QuickMIC® system in the US.The pre-clinical testing of the QuickMIC system has included about a hundred clinical patient samples and was performed at two reputable US clinical laboratories. The evaluation of Gradientech’s ultra-rapid antibiotic susceptibility testing (AST) system showed excellent performance and holds promises for the upcoming FDA study. Results from the US pre-clinical study will be presented at significant microbiology conferences during the next year.   “

    Gradientech receives QuickMIC® order from Iberlab in Portugal

    The diagnostic company Gradientech today announces the first order from their recently assigned distributor in Portugal.Iberlab is a leading supplier of diagnostic solutions and consumables to clinical laboratories in Portugal and was recently assigned as the commercial partner of Gradientech in the Portuguese market. Iberlab’s first installation of the QuickMIC[®] system is at Hospital Espirito Santo Évora. “It´s encouraging to see that the QuickMIC system is already out on its first commercial evaluation in Portugal. Portugal is an important market for us, with the need for rapid

    Gradientech announces oversubscribed rights issue

    Gradientech AB (publ) announces that the company's rights issue, for which the subscription period ended on December 6, 2023, has been completed. The issue was oversubscribed amounting to a total of approximately 107 percent. Through the issue, Gradientech will receive the maximum planned amount of approximately SEK 25.8 million before deduction of issue costs.“To oversubscribe a rights issue, without guarantors, in the current strained financing climate, is both gratifying and an acknowledgment that we have many shareholders who think that we both have a promising product and that we

    Gradientech: Interim report 1 January–30 September 2023

    Gradientech AB (publ) interim report for Q3 2023 is now available on the company's website www.gradientech.se.Third quarter 2023 · Net sales amounted to SEK 53 thousand (153). · Net profit/loss amounted to SEK -10,968 thousand (-11,640). · Earnings per share before and after dilution were SEK -0.62 (-0.73). · Cash flow from operating activities amounted to SEK -13,435 thousand (-10,706). · Cash and cash equivalents amounted to SEK 25,873 thousand (41,012) as of September 30, 2023. · Equity amounted to SEK 40,894 thousand (49,216) as of September 30, 2023. January–

    Gradientech signs exclusive contract with UK distributor

    The diagnostic company Gradientech today announces an exclusive distribution agreement with AB Scientific for the commercialisation of QuickMIC® in United Kingdom and Ireland.AB Scientific is a supplier of exclusive innovative products for all area of pathology from selected leading manufacturers across the world. “AB Scientific are at the forefront of improving diagnostics in the UK and Ireland with innovative and high-quality products, and the addition of the QuickMIC product line from Gradientech supports our mission. We have been focused on improvements to the Sepsis Pathway for

    Gradientech expands its distribution network in Europe

    The diagnostic company Gradientech today announces an exclusive distribution agreement with Iberlab for the commercialisation of QuickMIC® in Portugal.Iberlab is a leading supplier of diagnostic solutions and consumables to clinical laboratories on the Portuguese market. "At Iberlab, we aim to meet our customers’ requirements at the highest level. It is our strong ambition to provide diagnostic solutions to satisfy the needs of the clinical laboratory. Adding the product line from Gradientech is therefore a strong addition to our portfolio. The QuickMIC system fits our focus perfect as we

    QuickMIC® finalist in Applied Microbiology International Product of the Year Award

    The diagnostic company Gradientech today announces that the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) is a finalist in Applied Microbiology International Product of the Year Award 2023.The Applied Microbiology International Product of the Year award is awarded to a company who has brought to market a ground-breaking commercial product. Special consideration is given to those products that have addressed in some way one, or several, of the UNs Sustainable Development Goals. The product should represent any of the following qualities: a significant advancement

    Gradientech presents new QuickMIC® results at NSCMID 2023

    Gradientech will present new promising data from an ongoing study of the QuickMIC® rapid AST system at the the 39th annual NSCMID meeting in Örebro, Sweden, 21-24 September.Organised by the Nordic Society of Clinical Microbiology and Infectious Diseases, NSCMID aims at strengthening the bonds between clinicians and researchers in clinical microbiology and infectious diseases. The scientific program will include state of the art lectures from international experts, poster exhibition and young scientists’ session. “We are proud to participate and share new promising QuickMIC data from an

    Gradientech files patent application regarding early prediction of resistance mechanism using machine learning

    The diagnostics company Gradientech AB (publ) today announces that they have filed a patent application with the Swedish Patent and Registration Office (PRV). The patent application concerns the use of machine learning-based methods to be able to detect antibiotic resistance in patient samples at an early stage. Rapid detection and monitoring of resistance is of great importance as multidrug-resistant bacteria and specific multi-resistance genes can quickly spread in society and in healthcare.The patent application with priority date 30 August 2023 and entitled "Resistance And/or Resistance

    Gradientech: Interim report 1 January – 30 June 2023

    Gradientech AB (publ) interim report for Q2 2023 is now available on the company's website www.gradientech.se.Second quarter 2023 · Net sales amounted to SEK 1,141 thousand (4). · Net profit/loss amounted to SEK -16,837 thousand (-17,741). · Earnings per share before and after dilution were SEK -0.95 (-1.11). · Cash flow from operating activities amounted to SEK -14,399 thousand (-21,907). · Cash and cash equivalents amounted to SEK 39,535 thousand (51,821) as of June 30, 2023. · Equity amounted to SEK 35,112 thousand (60,857) as of June 30, 2023. · Within the

    QuickMIC® receives Breakthrough Device Designation from the U.S. Food and Drug Administration

    The diagnostics company Gradientech today announces that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device Designation for the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST). The Breakthrough Device Program is reserved for certain medical devices that provide more effective treatment or diagnosis than approved or cleared alternatives, and where the device availability is in the best interest of patients.The Breakthrough Device Program is intended to provide patients and health care providers with timely access to medical devices by

    Gradientech announces outcome of issue of convertible instruments

    Gradientech AB (publ) (“Gradientech” or “the Company”) announces that the Company's issue of convertible instruments with deviation from the pre-emption rights for existing shareholders has been completed. The final count in the issue shows that 815,823 convertible instruments were subscribed for. Through the issue, Gradientech will receive approximately SEK 16.7 million before deductions for transaction costs.OutcomeThe Board of Gradientech AB (publ) decided on 20 June 2023 through two separate decisions to issue maximum 1,220,000 convertible instruments with deviation from the pre-

    Gradientech presents QuickMIC® at FEMS 2023

    Gradientech will display its ultra-rapid and precise diagnostic system QuickMIC® at the FEMS Congress of European Microbiologists in Hamburg, Germany 9-13 July 2023.FEMS 2023 is the biggest event in Europe dedicated to showcasing the latest development of microbiology and connect to microbiologist from all over the world. Established in 1974, FEMS is a diverse federation of 55 European learned societies that includes around 30,000 professionals who are committed to advancing microbiology for the benefit of society. “We are excited to participate and showcase our innovative QuickMIC

    Gradientech starts pre-clinical testing in the US

    The diagnostics company Gradientech today announces the starting of pre-clinical testing in the US.Following the CE-IVD registration of the QuickMIC® system and gram-negative (GN) panel, the commercialisation has started in select European markets. While in Europe most laboratories follow the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, in the United States antimicrobial susceptibility testing is overwhelmingly performed according to criteria determined by the Clinical and Laboratory Standards Institute (CLSI). In addition to these different governing

    Gradientech presents QuickMIC® results at ASM Microbe 2023

    Gradientech announces the presentation of promising results from two collaborative studies on its ultra-rapid diagnostic system QuickMIC® at ASM Microbe in Houston, Texas 15 - 19 June 2023.Organized by the American Society for Microbiology , ASM Microbe is one of the largest microbial sciences conferences bringing together scientists, researchers, and healthcare professionals in the US. “We are very proud to present QuickMIC data and showcase our system for leading experts in the field. QuickMIC is the fastest

    Gradientech: Interim report 1 January – 31 March 2023

    Gradientech AB (publ) interim report for Q1 2023 is now available on the company's website www.gradientech.se.First quarter January-March 2023 · Net sales amounted to KSEK 380 (0). · Profit after tax amounted to KSEK -18,063 (-15,171). · Earnings per share before and after dilution were SEK -1.08 (-1.04). · Cash flow from operating activities amounted to KSEK -18,068 (-14,982). · Cash and cash equivalents on the balance sheet date amounted to KSEK 25,993 (74,020). · Equity as of March 31, 2023 amounted to KSEK 40,731 (78,598). · On January 18, 2023, the subscription

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media